Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $1,413,535 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,356,330 | $0 | $0 | $0 |
| Gross Profit | $57,205 | -$0 | -$0 | -$0 |
| % Margin | 4% | – | – | – |
| R&D Expenses | $27,180,640 | $42 | $26 | $42 |
| G&A Expenses | $0 | $30 | $27 | $21 |
| SG&A Expenses | $39,938,231 | $30 | $27 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $67,118,871 | $72 | $53 | $63 |
| Operating Income | -$67,061,666 | -$72 | -$53 | -$63 |
| % Margin | -4,744.3% | – | – | – |
| Other Income/Exp. Net | $3,084,974 | -$4 | -$6 | -$3 |
| Pre-Tax Income | -$63,976,692 | -$75 | -$59 | -$66 |
| Tax Expense | -$1,551,829 | $0 | $0 | $0 |
| Net Income | -$62,424,863 | -$75 | -$59 | -$66 |
| % Margin | -4,416.2% | – | – | – |
| EPS | -1.79 | -4.06 | -4.72 | -6.23 |
| % Growth | 55.9% | 14% | 24.2% | – |
| EPS Diluted | -1.79 | -4.06 | -4.72 | -6.23 |
| Weighted Avg Shares Out | 35 | 19 | 13 | 11 |
| Weighted Avg Shares Out Dil | 25 | 19 | 13 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | -$89,738 | $1 | $0 | $0 |
| Interest Expense | $283,128 | $3 | $2 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$67,061,666 | -$72 | -$57 | -$64 |
| % Margin | -4,744.3% | – | – | – |